Navigation Links
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Date:3/25/2009

--Company Now Has Until October 26, 2009 to Regain Compliance with $1.00 Minimum Bid Price Rule--

TUSTIN, Calif., March 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has received a letter from NASDAQ that provides Peregrine with an additional three months to regain compliance with the minimum bid price rule. Peregrine now has until October 26, 2009 to regain compliance with NASDAQ's $1.00 minimum bid price rule in order to remain listed on The Nasdaq Stock Market. This extension was granted as part of NASDAQ's recently announced temporary suspension of the minimum bid price and market value requirements for all NASDAQ-listed companies.

As previously announced, in December 2008 Peregrine received a letter from NASDAQ informing the company that the deadline for regaining compliance with the minimum bid price rule had been extended until July 27, 2009. This deadline is now extended until October 26, 2009, at which time Peregrine must evidence a closing bid price of $1.00 or more for a minimum of 10 prior consecutive trading days.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... New York, NY (PRWEB) April 26, 2015 ... is composed of both inpatient and outpatient therapy facilities ... In the five years to 2015, the industry has ... population and increasing acceptance of the benefits of physical ... older has also helped support industry revenue growth during ...
(Date:4/26/2015)... April 26, 2015 A Case ... in the U.S. District Court, Northern District of ... http://www.testosteronelawsuithub.com/ ) have been consolidated for the ... documents, matters addressed included the intention of certain ... involving their products on preemption grounds, with the ...
(Date:4/26/2015)... Italian public health researchers have released ... cement plants and other asbestos-related industries. Surviving Mesothelioma has ... Click here to read it now. , ... and Environmental Medicine analyzed more than 15,000 cases of ... where the asbestos cancer was most common. , ...
(Date:4/26/2015)... released a new blog post explaining how to find ... find low cost auto insurance is by comparing quotes. Drivers ... a simple and convenient way. It is no longer necessary ... All the details are now freely available to anyone on ... to compare online car insurance quotes on a single website. ...
(Date:4/26/2015)... Indiana (PRWEB) April 26, 2015 Indiana ... service provider announces that Brotherhood Mutual Insurance Company has ... Armstrong, Manager of Network Infrastructure at Brotherhood Mutual Insurance ... and the service reliability Brotherhood Mutual needed. ... diversity, and IFN worked with us to ensure we ...
Breaking Medicine News(10 mins):Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 4Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3
... News) -- People affected by epilepsy are nearly eight ... schizophrenia, and those with schizophrenia are also six times ... not schizophrenic, a new study suggests. Researchers in ... may be due to genetic, environmental or neurobiological causes. ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Talking with doctors about cancer and cancer treatments can feel ... often need help to understand their treatment options, and the ... making life and death decisions that may affect their survival ... Cancer treatments and tests can be serious. Patients need to ...
... DURHAM, N.C. An analysis of more than 30,000 cancer ... complication than doctors may realize, causing additional hospitalizations and driving ... by a Duke Cancer Institute researcher. The study, which ... Cancer Congress in Stockholm, found that as many as one ...
... based method of family planning developed by researchers from ... so effectively meets the needs of users that they continue ... finds that women who follow the Standard Days Method, are ... effectively. Results of the large, multi-country study of 1659 women ...
... new type of nanoparticle developed in the laboratories at the ... delivery of chemotherapy to treat cancer. Wenbin Lin, PhD, ... their finding in the Sept. 14, 2011 issue of ... laboratory studies, Lin and colleagues developed and tested a new ...
Cached Medicine News:Health News:Researchers Find Link Between Epilepsy, Schizophrenia Risk 2Health News:10 ways to make better decisions about cancer care 2Health News:10 ways to make better decisions about cancer care 3Health News:Costly blood clots more common than expected among cancer patients 2Health News:Long-term effectiveness of new family planning method shown in study 2Health News:UNC scientist proves potential of new nanoparticle design for cancer therapy 2
(Date:4/26/2015)... , April 26, 2015  Ikonopedia announced ... MQSA management system have been selected for use ... of breast screening and diagnostic examinations. Ikonopedia will ... the Society of Breast Imaging,s SBI/ACR Breast Imaging ... April 25-28, 2015 (SBI Booth #216). ...
(Date:4/26/2015)... April 26, 2015 Cancer experts have reported ... supported project in the area of distributed learning is ... the benefit of patients. Speakers at a Varian-hosted symposium ... Oncology) forum in Barcelona detailed ... applying that knowledge to help benefit the next patient. ...
(Date:4/25/2015)... April 2015 Hospira, Inc. ... Entwicklung von Biosimilar-Behandlungen, sprach heute auf der jährlichen ... (EGA) in London über ... Verfügbarkeit von Biosimilars für Patienten. Das ... Papers mit dem Titel „Why extrapolation is ...
Breaking Medicine Technology:Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 2Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 3Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 4Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 2Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8
... Landauer, Inc. (NYSE: LDR) announced today that ... of $0.55 per share for the second quarter of fiscal ... shareholders of record on March 9, 2012. ... technical and analytical services to determine occupational and environmental radiation ...
... 2012  In an effort to maximize business impact and ... research leaders must constantly evaluate the manner in which ... understand the optimal balance of external contract employees in ... quickly changing healthcare industry. To identify innovative ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
Athouritative, on the spot answers for acute care and consultations....
... The SphygmoCor Mx Central Blood Pressure ... the SphygmoCor Px system by providing ... pressure waveform., ,Key cardiovascular parameters are ... These parameters include:, Central Systolic, ...
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps....
Medicine Products: